On February 10, 2022 Palatin Technologies, Inc. (NYSE American: PTN) reported that it will announce its second quarter, fiscal year 2022 operating results on Tuesday, February 15, 2022, before the open of the U.S. financial markets (Press release, Palatin Technologies, FEB 10, 2022, View Source [SID1234607969]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 15, 2022, at 11:00 a.m. ET. The conference call will include a review of the company’s operating results and an update on programs under development.

The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin’s website at View Source

On February 10, 2022 SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and Telix Pharmaceuticals LTD (Telix), a biopharmaceutical company headquartered in Australia, reported the signing of a clinical supply agreement that provides Telix with SHINE’s non-carrier-added (n.c.a.) lutetium-177 (Lu-177) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer (Press release, Shine Medical Technologies, FEB 10, 2022, View Source [SID1234607968]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SHINE will immediately commence supply of n.c.a. Lu-177 for use in clinical trials of Telix’s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer), with particular focus on the US market.

"There continues to be a growing, critical need for more effective treatment of metastatic or late-stage cancers," said Greg Piefer, SHINE’s founder and CEO. "Our exciting partnership with Telix allows us to bring hope to these patients as we continue to help deliver Lu-177 for highly precise treatments that produce little damage in the tissue around treatment sites."

SHINE’s Therapeutics division produces n.c.a. Lu-177, a low-energy beta-particle emitter, which can be paired with a targeting molecule (such as an antibody or peptide) to directly target and irradiate cancer cells. Several Lu-177 therapies are currently being developed to treat various forms of cancer and may provide alternative treatment options for patients where other therapeutic solutions have proven insufficient.

Dr. Gabriel Liberatore, Telix Group Chief Operating Officer continued, "SHINE’s investment in high quality isotope production places them at the forefront of the radiopharmaceutical supply chain with particular strength in servicing the US market. The agreement with SHINE supports our goal to establish a global supply chain with the capacity and reliability to support an increasing level of clinical activity through Telix-sponsored and investigator-led studies and to scale-up to commercial stage."

On February 10, 2022 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 23rd, at 4:30 p.m. ET to discuss fourth quarter and full year 2021 financial results and provide a general business update (Press release, BioMarin, FEB 10, 2022, View Source,-February-23-at-4-30pm-ET [SID1234607967]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioMarin to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on Wed., February 23 at 4:30pm ET

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com. A replay of the call will be archived on the site for one week following the call.

On February 10, 2022 Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, reported that Dr. Ivor Royston, the company’s President and Chief Executive Officer, is scheduled to present at the 11th Annual SVB Leerink Global Healthcare Conference, on Thursday, February 17, 2022, at 5:00 p.m. ET (Press release, Viracta Therapeutics, FEB 10, 2022, View Source [SID1234607966]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" at View Source The webcast will be archived for 60 days.

On February 10, 2022 CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), reported that it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate, CVSQIV, developed in collaboration with GSK (Press release, CureVac, FEB 10, 2022, View Source [SID1234607965]). The differentiated multivalent vaccine candidate features multiple non-chemically modified mRNA constructs to induce immune responses against relevant targets of four different influenza strains. The use of customizable and rapidly produced mRNAs to address influenza could enable faster development and delivery of potentially improved vaccine candidates, featuring even short-term strain updates for the approaching influenza season.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Providing seasonally updated yet highly effective influenza vaccines has historically been challenging. The successful implementation of mRNA technology to address the global COVID-19 pandemic has demonstrated a tremendous opportunity for this platform," said Dr. Klaus Edvardsen, Chief Development Officer of CureVac. "Leveraging the inherent flexibility of our mRNA platform together with our fast manufacturing, we have successfully combined multiple different mRNAs in a single candidate with the goal to develop a potentially improved vaccine for seasonal influenza. We believe this represents an important advancement of this key technology."

The Phase 1 dose-escalation study is being conducted in Panama and is expected to enroll up to 240 healthy adult participants to evaluate the safety, reactogenicity and immunogenicity of CVSQIV. In line with the mRNA development strategy in collaboration with GSK, both companies are also working on chemically modified mRNA technologies with clinical programs for influenza and COVID-19 expected to start later this year.

The CureVac-GSK infectious disease collaboration was first announced in July 2020 and focuses on the development of new products based on CureVac’s mRNA technology for different targets in the field of infectious diseases.

About CVSQIV

CVSQIV is the first seasonal influenza vaccine candidate in clinical development based on an advanced mRNA backbone developed by CureVac and is one of the second-generation mRNA vaccine candidates from the infectious disease program developed in collaboration with GSK. The differentiated candidate combines multiple separate non-chemically modified mRNA constructs encoding for antigens that address four different influenza strains. The Phase 1, open-label, dose-escalation study will assess the safety, reactogenicity and immunogenicity of CVSQIV in the dose range of 3 to 28µg in the predefined age groups of 18-55 years and 65 years and above. The study is expected to enroll up to 240 healthy participants and is being conducted in Panama. A clinical study to test the use of chemically modified mRNA is expected to begin later this year.